Home » 2018 » August
Pfizer DMD drug domagrozumab fails in two clinical trials

Pfizer DMD drug domagrozumab fails in two clinical trials

Pfizer DMD drug update : US pharma giant Pfizer will scrap a couple of ongoing clinical trials evaluating its humanized monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD) owing to negative results. The two trials of the Pfizer DMD drug are B5161002 – a phase 2 safety and efficacy study and […]

Amgen blood cancer drug BLINCYTO scores EC approval in pediatric patients

The European Commission (EC) has approved an expanded indication for Amgen blood cancer drug BLINCYTO (blinatumomab) as monotherapy for the treatment of certain form of acute lymphoblastic leukemia (ALL) in pediatric patients aged one year or older. The pediatric approval of BLINCYTO is for the treatment of patients with Philadelphia chromosome-negative (Ph-) CD19 positive B-cell […]

Continue reading …
Understanding Lyme Disease as the Great Imitator

For most adults and children, getting a tick bite is not a concerning experience. However, the increase in the number of cases of Lyme Disease throughout the world over the last several years has brought tick bites into the spotlight. In the UK, there are an estimated 1,000 cases of Lyme Disease diagnosed each year, […]

Continue reading …
Urovant licenses overactive bladder gene therapy hMaxi-K from Ion Channel

Urovant Sciences has acquired global licensing rights for the development and commercialization of a gene therapy called hMaxi-K from Ion Channel Innovations, which is being developed for the treatment of overactive bladder (OAB) in patients who did not respond to oral pharmacologic therapy. As of now, there are no treatments for overactive bladder that have […]

Continue reading …
FDA approves IMBRUVICA, rituximab combo for rare blood cancer

Janssen Pharmaceutical has bagged approval from the US Food and Drug Administration (FDA) for its combo of IMBRUVICA (ibrutinib) and rituximab for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cancer. The FDA approval secured by the Johnson & Johnson subsidiary expands IMBRUVICA’s current label in Waldenström’s macroglobulinemia as a monotherapy to include its […]

Continue reading …
Cantex acute myeloid leukemia drug CX-01gets FDA fast track designation

Cantex Pharmaceuticals, a Florida-based biotech company, has secured the fast track designation for its acute myeloid leukemia drug CX-01 from the US Food and Drug Administration (FDA). The FDA fast track designation for CX-01 is for the treatment of patients, aged over 60, who are being subjected to induction therapy for newly diagnosed acute myeloid […]

Continue reading …
LEO Pharma bags licensing rights for atopic dermatitis drug JW1601 from JWP

LEO Pharma, a Danish pharma company, has bagged global exclusive rights for atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP) in a deal worth around KRW450 billion ($402 million). The global licensing agreement will not cover South Korea, the home country of JWP, where the Korean pharma company will keep its exclusive rights over the […]

Continue reading …
Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients

Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]

Continue reading …
PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics

US biopharma company PTC Therapeutics has completed its $200 million acquisition of Agilis Biotherapeutics, a biotechnology company engaged in the development of gene therapies for rare genetic disorders that affect the central nervous system (CNS). PTC Therapeutics acquisition of Agilis Biotherapeutics adds an adeno-associated virus (AAV) gene therapy called GT-AADC to the former’s portfolio. GT-AADC […]

Continue reading …
Ortho Dermatologics bags FDA approval for Altreno lotion for acne treatment

Altreno FDA approval : Ortho Dermatologics, a division of Bausch Health Companies, has bagged approval from the US Food and Drug Administration (FDA) for Altreno lotion (tretinoin 0.05%) for the topical treatment of acne vulgaris in patients aged 9 years and older. According to Bausch Health Companies, Altreno is the first formulation of tretinoin in […]

Continue reading …
Page 1 of 41234